JRCT ID: jRCT2031240141
Registered date:04/06/2024
General Drug Use-Results Survey of COMLEX OTIC SOLUTION 1.5%
Basic Information
Recruitment status | Recruiting |
---|---|
Health condition(s) or Problem(s) studied | Otitis externa, Chronic otitis media, and Acute otitis media |
Date of first enrollment | 04/06/2024 |
Target sample size | 300 |
Countries of recruitment | |
Study type | Observational |
Intervention(s) | none |
Outcome(s)
Primary Outcome | Examine the safety of the drug when administered under routine medical care. In conjunction, the efficacy of this drug also be examined. |
---|---|
Secondary Outcome |
Key inclusion & exclusion criteria
Age minimum | Not applicable |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | Patients treated with this drug for otitis externa, chronic otitis media, and acute otitis media |
Exclude criteria | N/A |
Related Information
Primary Sponsor | CEOLIA Pharma.Co.Ltd Pharmacovigilance Office |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) |
Contact
Public contact | |
Name | Pharmacovigilance Office CEOLIA Pharma.Co.Ltd |
Address | 2F, 2-13-10, Torigoe, Taito-ku, Tokyo Tokyo Japan 111-0054 |
Telephone | +81-3-5829-5878 |
2030_ceo@ceolia.co.jp | |
Affiliation | CEOLIA Pharma.Co.Ltd |
Scientific contact | |
Name | Pharmacovigilance Office CEOLIA Pharma.Co.Ltd |
Address | 2F, 2-13-10, Torigoe, Taito-ku, Tokyo Tokyo Japan 111-0054 |
Telephone | +81-3-5829-5878 |
2030_ceo@ceolia.co.jp | |
Affiliation | CEOLIA Pharma.Co.Ltd |